drugset
drugset / Trial / NCT07287163

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

NCT07287163 ↗

Phase 3 Enrolling by invitation 700 enrolled Praxis Precision Medicines
NaSingle-groupOpen-labelTreatment

Summary

Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy

Timeline

Start
2025-10-27
Primary completion
2028-05-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject vormatrogine Unknown 30 mg Oral

Indications

epilepsy with generalized tonic-clonic seizures focal epilepsy